Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00.

Beam Therapeutics (BEAM) presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin ...

Two Massachusetts researchers are among the recipients of an award known as the “Oscars of Science” for their research in ...

KLP Kapitalforvaltning AS purchased a new stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) in the fourth ...

JBL is set to launch Tune Series 2 in India with ANC, 48-hour battery, and app control starting at ₹5XX9 this month.

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose ...

Shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) have earned an average recommendation of “Buy” from the ...

GreenLight Biosciences, Inc., a Boston-based agtech company with lab, office and greenhouse space in RTP, has closed a Series C funding round, including a $25 million investment from a new investor, ...

The technology, which in the past had been limited by size and cost, provides targeted doses of radiation to tumors, ...

AIR-001 is designed to restore functional alpha-1 antitrypsin (M-AAT) protein production by precisely repairing the SERPINA1 mutation (PiZ) to address the underlying cause of both lung and liver ...

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Beam ...